Seventy-one adults with advanced STS who received @ prior chemotherapeutics were randomized to selumetinib @ mg p.o. bid and allowed to crossover upon progression , or to selumetinib @ mg p.o. bid plus temsirolimus @ mg i.v. weekly , with primary endpoint of progression-free survival ( PFS ) .